<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533077</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-117</org_study_id>
    <nct_id>NCT01533077</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa</brief_title>
  <official_title>Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA
      9-1067 or 1 hour after.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-centre, open-label, randomized, gender-balanced, crossover study with four consecutive
      single-dose treatment periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration (L-DOPA)</measure>
    <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time of Occurrence of Cmax Maximum Observed Plasma Concentration (L-DOPA)</measure>
    <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA). For tmax = time to Cmax values are presented as median with range values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (L-DOPA)</measure>
    <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (L-DOPA)</measure>
    <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration (3-OMD)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
    <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Occurrence of Cmax (3-OMD)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
    <description>Pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD). For tmax = time to Cmax values are presented as median with range values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (3-OMD)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (3-OMD)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration (Carbidopa)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of carbidopa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Occurrence of Cmax (Carbidopa)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (Carbidopa)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of carbidopa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (Carbidopa)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
    <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration (BIA 9-1067)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Occurrence of Cmax (BIA 9-1067)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Pharmacokinetic parameters of BIA 9-1067. For tmax = time to Cmax values are presented as median with range values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (BIA 9-1067)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (BIA 9-1067)</measure>
    <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
    <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>50 mg of BIA 9-1067 (single-dose)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet® 100/25 mg</intervention_name>
    <description>immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>levodopa 100 mg /carbidopa 25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability for the entire study period and willingness to adhere to the protocol
             requirements as evidenced by the informed consent form (ICF) duly read, signed and
             dated by the volunteer prior to participation in the study.

          -  Male or female volunteers.

          -  Volunteers of at least 18 years of age but not older than 45 years.

          -  Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2.

          -  Volunteers who were healthy as determined by pre-study (at screening) medical history,
             physical examination, vital signs, complete neurological examination and 12-lead ECG.

          -  Volunteers who had clinical laboratory test results judged clinically acceptable
             (within the laboratory's stated normal range; if not within this range, they must had
             been without any clinical significance) at screening and admission to first treatment
             period.

          -  Volunteers who had negative tests for hepatitis B surface antigen (HBsAg),
             anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2
             antibodies (HIV-1 and HIV-2 Ab) at screening.

          -  Volunteers who had negative screen of ethyl alcohol and drugs of abuse at screening.

          -  Volunteers who were non- or ex-smokers. For the purpose of this study, an ex-smoker is
             defined as someone who completely stopped smoking for at least 3 months before day 1
             of this study.

          -  Due to unknown risks and potential harm to the unborn fetus, sexually active men or
             women must have agreed to use a medically acceptable form of contraception throughout
             the study.

          -  If female of childbearing potential, she had a negative HCG beta serum pregnancy test
             at screening and admission to each treatment period

          -  The informed consent form must have been signed by all volunteers, prior to their
             participation in the study.

        Exclusion Criteria:

          -  Volunteers who did not conform to the above inclusion criteria, or in case of

          -  Volunteers who had a clinically relevant surgical history.

          -  Volunteers who had a clinically relevant family history.

          -  Volunteers who had a history of relevant atopy.

          -  Volunteers who had a significant infection or known inflammatory process at screening
             or admission to the treatment period.

          -  Volunteers who had acute gastrointestinal symptoms at the time of screening or
             admission to the treatment period (e.g., nausea, vomiting, diarrhoea, heartburn).

          -  Volunteers who were vegetarians, vegans or have medical dietary restrictions.

          -  Volunteers who could not communicate reliably with the investigator.

          -  Volunteers who were unlikely to co-operate with the requirements of the study.

          -  History of hypersensitivity to BIA 9-1067, tolcapone, entacapone, levodopa,
             benserazide or any related products (including excipients of the formulations) as well
             as severe hypersensitivity reactions (like angioedema) to any drugs.

          -  Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects.

          -  History of significant gastrointestinal, liver or kidney disease that may affect drug
             bioavailability.

          -  Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic,
             dermatologic or connective tissue disease.

          -  Suicidal tendency, history of or disposition to seizures, state of confusion,
             clinically relevant psychiatric diseases.

          -  Presence of significant heart disease or disorder according to ECG.

          -  Presence of suspicious undiagnosed skin lesions or a history of melanoma.

          -  Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic
             rhabdomyolysis.

          -  History of significant glaucoma.

          -  Used of prescription medications including monoamine oxidase (MAO) inhibitors within
             28 days before day 1 of the study.

          -  Used of over-the-counter (OTC) products within 7 days before day 1 of the study.

          -  Maintenance therapy with any drug, or significant history of drug dependency (drug
             abuse) or alcohol abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol,
             acute or chronic).

          -  Any clinically significant illness in the previous 28 days before day 1 of this study.

          -  Volunteers who took an Investigational Product (in another clinical trial) or donated
             50 mL or more of blood in the previous 28 days before day 1 of this study.

          -  Poor motivation, intellectual problems likely to limit the validity of consent to
             participate in the study or limit the ability to comply with the protocol requirements
             or inability to cooperate adequately, inability to understand and to observe the
             instructions of the physician.

          -  Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies, etc.) in the previous 56 days before day 1 of this study.

          -  Positive urine screening of ethyl alcohol or drugs of abuse at admission to the
             treatment period.

          -  Any history of tuberculosis and/or prophylaxis for tuberculosis.

          -  Positive results to HIV, HBsAg or anti-HCV tests.

          -  Participation in any previous clinical study with BIA 9-1067 within 84 days before day
             1 of the study.

          -  Females who were pregnant according to a positive serum pregnancy test or were
             lactating.

          -  Females of childbearing potential who refused to use an acceptable contraceptive
             regimen throughout the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2015</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Opicapone</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BIA 9-1067 50 mg</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sinemet® 100/25</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BIA 9-1067 50 mg + Sinemet® 100/25</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sinemet® 100/25 1 h After the BIA 9-1067</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
BIA 9-1067: 50 mg of BIA 9-1067 (single-dose)
Sinemet® 100/25 mg: immediate-release levodopa/carbidopa 100/25 (single-dose).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration (L-DOPA)</title>
        <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
        <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration (L-DOPA)</title>
          <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1070" spread="328"/>
                    <measurement group_id="O2" value="1105" spread="363"/>
                    <measurement group_id="O3" value="1198" spread="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time of Occurrence of Cmax Maximum Observed Plasma Concentration (L-DOPA)</title>
        <description>Pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA). For tmax = time to Cmax values are presented as median with range values.</description>
        <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time of Occurrence of Cmax Maximum Observed Plasma Concentration (L-DOPA)</title>
          <description>Pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA). For tmax = time to Cmax values are presented as median with range values.</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (L-DOPA)</title>
        <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
        <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (L-DOPA)</title>
          <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2289" spread="729"/>
                    <measurement group_id="O2" value="2611" spread="916"/>
                    <measurement group_id="O3" value="2459" spread="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (L-DOPA)</title>
        <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
        <time_frame>pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (L-DOPA)</title>
          <description>Mean pharmacokinetic parameters of L-beta-3,4-dihydroxyphenylalanine (levodopa) (L-DOPA)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2397" spread="741"/>
                    <measurement group_id="O2" value="2730" spread="913"/>
                    <measurement group_id="O3" value="2603" spread="836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration (3-OMD)</title>
        <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration (3-OMD)</title>
          <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" spread="175"/>
                    <measurement group_id="O2" value="336" spread="127"/>
                    <measurement group_id="O3" value="401" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Occurrence of Cmax (3-OMD)</title>
        <description>Pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD). For tmax = time to Cmax values are presented as median with range values.</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Occurrence of Cmax (3-OMD)</title>
          <description>Pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD). For tmax = time to Cmax values are presented as median with range values.</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="5.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (3-OMD)</title>
        <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (3-OMD)</title>
          <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10296" spread="3151"/>
                    <measurement group_id="O2" value="6940" spread="2504"/>
                    <measurement group_id="O3" value="8149" spread="2809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (3-OMD)</title>
        <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (3-OMD)</title>
          <description>Mean pharmacokinetic parameters of 3-O-methyl-levodopa (3-OMD)</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11193" spread="3187"/>
                    <measurement group_id="O2" value="7730" spread="2578"/>
                    <measurement group_id="O3" value="89962" spread="2803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration (Carbidopa)</title>
        <description>Mean pharmacokinetic parameters of carbidopa</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration (Carbidopa)</title>
          <description>Mean pharmacokinetic parameters of carbidopa</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="56.2"/>
                    <measurement group_id="O2" value="136" spread="62.0"/>
                    <measurement group_id="O3" value="142" spread="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Occurrence of Cmax (Carbidopa)</title>
        <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Occurrence of Cmax (Carbidopa)</title>
          <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (Carbidopa)</title>
        <description>Mean pharmacokinetic parameters of carbidopa</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (Carbidopa)</title>
          <description>Mean pharmacokinetic parameters of carbidopa</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656" spread="226"/>
                    <measurement group_id="O2" value="670" spread="253"/>
                    <measurement group_id="O3" value="732" spread="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (Carbidopa)</title>
        <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Sinemet® 100/25 mg</title>
            <description>Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (Carbidopa)</title>
          <description>Pharmacokinetic parameters of carbidopa. For tmax = time to Cmax values are presented as median with range values.</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668" spread="224"/>
                    <measurement group_id="O2" value="683" spread="253"/>
                    <measurement group_id="O3" value="745" spread="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration (BIA 9-1067)</title>
        <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration (BIA 9-1067)</title>
          <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648" spread="264"/>
                    <measurement group_id="O2" value="625" spread="346"/>
                    <measurement group_id="O3" value="628" spread="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Occurrence of Cmax (BIA 9-1067)</title>
        <description>Pharmacokinetic parameters of BIA 9-1067. For tmax = time to Cmax values are presented as median with range values.</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Occurrence of Cmax (BIA 9-1067)</title>
          <description>Pharmacokinetic parameters of BIA 9-1067. For tmax = time to Cmax values are presented as median with range values.</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.50" lower_limit="0.50" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (BIA 9-1067)</title>
        <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (BIA 9-1067)</title>
          <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2094" spread="904"/>
                    <measurement group_id="O2" value="2130" spread="1248"/>
                    <measurement group_id="O3" value="2245" spread="1171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (BIA 9-1067)</title>
        <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
        <time_frame>Pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h after dose.</time_frame>
        <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
            <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly BIA 9-1067 Levodopa 100 mg Carbidopa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (BIA 9-1067)</title>
          <description>Mean pharmacokinetic parameters of BIA 9-1067</description>
          <population>According to the protocol, the “pharmacokinetic population” should include all subjects who had valid data for all treatment periods. In this study, 18 subjects completed 2 treatment periods, 17 subjects completed 3 treatment periods and 16 subjects completed all 4 treatment periods.</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2165" spread="913"/>
                    <measurement group_id="O2" value="2360" spread="1281"/>
                    <measurement group_id="O3" value="2678" spread="1334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 50 mg.</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Separated 1 h</title>
          <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg separated 1 h.</description>
        </group>
        <group group_id="E3">
          <title>BIA 9-1067 50 mg + Sinemet® 100/25 mg Concomitantly</title>
          <description>BIA 9-1067 50 mg + Sinemet® 100/25 mg concomitantly.</description>
        </group>
        <group group_id="E4">
          <title>Sinemet® 100/25 mg</title>
          <description>Sinemet® 100/25 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

